{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:50:59Z","timestamp":1775515859743,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The combination of milbemycin oxime (MO) and lotilaner (Credelio<jats:sup>\u00ae<\/jats:sup>Plus) is a novel systemic endectocide that provides month-long effectiveness in dogs after a single oral treatment. The safety of Credelio<jats:sup>\u00ae<\/jats:sup>Plus flavored chewable tablets was investigated in three target animal safety studies. Two studies (one in juveniles and one in adults) evaluated the long-term safety, and one study evaluated the acute safety of the product when administered orally at the upper end of the recommended dose range (0.75\u20131.53\u00a0mg\/kg MO and 20\u201341\u00a0mg\/kg lotilaner) and multiples of this dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The objectives of these studies were to determine the long-term and acute safety of MO and lotilaner flavored chewable tablets in healthy dogs. All three studies were randomized, blinded, parallel-group design studies in healthy Beagle dogs. In each of the two long-term studies, 32 dogs were randomized among four groups to untreated controls or to treated groups at target doses of 1X, 3X, or 5X. Treatment was administered on seven (adult dogs) or nine (juvenile dogs) occasions with dosing every 4 weeks. In the acute study, 48 dogs were randomized among four groups to untreated controls or to treated groups at 1X, 3X, or 6X. In all three studies, the control group was administered placebo tablets. All dogs were fed 30 to 45\u00a0min prior to treatment and the assessment of safety was based on health observations, complete physical\/neurological examinations, and food consumption. For the long-term safety studies, safety assessments also included clinical pathology evaluations (hematology, clinical chemistry and urinalysis), body weight, pharmacokinetic blood collections, and macroscopic and microscopic examinations of collected tissues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MO and lotilaner did not induce any treatment-related adverse effects based on health observations, physical\/neurological examinations, or food consumption in the long-term or acute studies. Additionally, in the long-term studies, MO and lotilaner did not induce any treatment-related effects on clinical pathology, body weight, and macroscopic and microscopic examinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These three studies demonstrate that Credelio<jats:sup>\u00ae<\/jats:sup>Plus has a wide safety margin when administered at monthly intervals to puppies and dogs at the high end of the commercial dose band.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical Abstract<\/jats:title><\/jats:sec>","DOI":"10.1186\/s13071-021-04760-z","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:26:26Z","timestamp":1622161586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio\u00ae Plus) in juvenile and adult dogs"],"prefix":"10.1186","volume":"14","author":[{"given":"Kari L.","family":"Riggs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"4760_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s13071-017-2476-y","volume":"10","author":"M Murphy","year":"2017","unstructured":"Murphy M, Garcia R, Karadzovska D, Cavalleri D, Snyder D, Seewald W, Real T, Drake J, Wiseman S, Nanchen S. Laboratory evaluations of the immediate and sustained efficacy of lotilaner (Credelio\u2122) against four common species of ticks affecting dogs in North America. Parasit Vectors. 2017;10:523.","journal-title":"Parasit Vectors"},{"key":"4760_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13071-019-3873-1","volume":"13","author":"L Young","year":"2020","unstructured":"Young L, Karadzovska D, Wiseman S, Helbig R. Efficacy of lotilaner (Credelio\u2122) against the adult cat flea, Ctenocephalides felis and flea eggs following oral administration to dogs. Parasit Vectors. 2020;13:25.","journal-title":"Parasit Vectors"},{"key":"4760_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13071-018-2970-x","volume":"11","author":"I Wright","year":"2018","unstructured":"Wright I. Lotilaner - a novel formulation for cats provides systemic tick and flea control. Parasit Vectors. 2018;11:407.","journal-title":"Parasit Vectors"},{"key":"4760_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s13071-017-2472-2","volume":"10","author":"DE Snyder","year":"2017","unstructured":"Snyder DE, Wiseman S, Liebenberg JE. Efficacy of lotilaner (Credelio\u2122), a novel oral isoxazoline against naturally occurring mange mite infestations in dogs caused by Demodex spp. Parasit Vectors. 2017;10:532.","journal-title":"Parasit Vectors"},{"issue":"2\u20134","key":"4760_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.vetpar.2011.11.012","volume":"184","author":"B Schnitzler","year":"2012","unstructured":"Schnitzler B, Hayes B, Wiseman S, Snyder DE. Confirmation of the efficacy of a combination tablet of spinosad and milbemycin oxime against naturally acquired infections of canine intestinal nematode parasites. Vet Parasitol. 2012;184(2\u20134):279\u201383.","journal-title":"Vet Parasitol"},{"issue":"3\u20134","key":"4760_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.vetpar.2011.03.034","volume":"180","author":"DE Snyder","year":"2011","unstructured":"Snyder DE, Wiseman S, Bowman DD, McCall JW, Reinemeyer CR. Assessment of the effectiveness of a combination product of spinosad and milbemycin oxime on the prophylaxis of canine heartworm infection. Vet Parasitol. 2011;180(3\u20134):262\u20136.","journal-title":"Vet Parasitol"},{"issue":"1\u20132","key":"4760_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.vetpar.2014.07.023","volume":"205","author":"DD Bowman","year":"2014","unstructured":"Bowman DD, Reinemeyer CR, Wiseman S, Snyder DE. Efficacy of milbemycin oxime in combination with spinosad in the treatment of larval and immature adult stages of Ancylostoma caninum and Toxocara canis in experimentally infected dogs. Vet Parasitol. 2014;205(1\u20132):134\u20139.","journal-title":"Vet Parasitol"},{"key":"4760_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-308X(08)00204-2","volume":"66","author":"JW McCall","year":"2008","unstructured":"McCall JW, Genchi C, Kramer LH, Guerrero J. Heartworm disease in animals and humans (Chapter 4). Adv Parasitol. 2008;66:193\u2013285.","journal-title":"Adv. Parasitol."},{"issue":"6","key":"4760_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cvsm.2009.06.003","volume":"39","author":"DD Bowman","year":"2009","unstructured":"Bowman DD, Atkins Clarke E. Heartworm biology, treatment, and control. Vet Clin North Am Small Anim Pract. 2009;39(6):1127\u201358.","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"4760_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1756-3305-5-138","volume":"5","author":"DD Bowman","year":"2012","unstructured":"Bowman DD. Heartworms, macrocyclic lactones, and the specter of resistance to prevention in the United States. Parasit Vectors. 2012;5:138.","journal-title":"Parasit Vectors"},{"key":"4760_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.vetpar.2013.10.024","volume":"199","author":"C B\u00f6hm","year":"2014","unstructured":"B\u00f6hm C, Schnyder M, Thamsborg SM, Thompson CM, Trout C, Wolken S, et al. Assessment of the combination of spinosad and milbemycin oxime in preventing the development of canine Angiostrongylus vasorum infections. Vet Parasitol. 2014;199:272.","journal-title":"Vet Parasitol"},{"key":"4760_CR12","unstructured":"VICH GL 43: Guideline on target animal safety for veterinary pharmaceutical products. Belgium; 2008.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500004361.pdf. Accessed 25 Nov 2020."},{"key":"4760_CR13","unstructured":"OECD series on Principles of Good Laboratory Practice (GLP)\u00a0and compliance monitoring. 1998. http:\/\/www.oecd.org\/chemicalsafety\/testing\/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm. Accessed 25 Nov 2020."},{"key":"4760_CR14","unstructured":"21 CFR\u00a0Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies Reference.\u00a0U.S. Government Printing Office via GPO Access, 2005. https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?SID=e7ecfefdc4380c6cf81ee5b7b0af006a&mc=true&node=pt21.1.58&rgn=div5. Accessed 25 Nov 2020."},{"issue":"2","key":"4760_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/0976-500X.72351","volume":"1","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother. 2010;1(2):94\u20139.","journal-title":"J Pharmacol Pharmacother"},{"key":"4760_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s13071-017-2475-z","volume":"10","author":"CE Toutain","year":"2017","unstructured":"Toutain CE, Seewald W, Jung M. The intravenous and oral pharmacokinetics of lotilaner in dogs. Parasit Vectors. 2017;10:522.","journal-title":"Parasit Vectors"},{"key":"4760_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1079\/9780851996172.0051","volume-title":"Macrocyclic lactones in antiparasitic therapy (Chapter 1.3)","author":"M Jung","year":"2002","unstructured":"Jung M, Saito A, Buescher G, Maurer M, Graf J-F. Macrocyclic lactones in antiparasitic therapy (Chapter 1.3). New York: CABI Publishing; 2002. p. 51\u201374."},{"key":"4760_CR18","unstructured":"European Medicines Agency, Committee for Medicinal Products for Veterinary Use, Credelio\u00ae European Product Information. 2017.\u00a0http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/veterinary\/004247\/WC500227518.pdf. Accessed 25 Nov 2020."},{"issue":"4","key":"4760_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2885.2011.01333.x","volume":"35","author":"SD Holmstrom","year":"2011","unstructured":"Holmstrom SD, Totten ML, Newhall KB, Qiao M, Riggs KL. Pharmacokinetics of spinosad and milbemycin oxime administered in combination and separately per os to dogs. J Vet Pharmacol Ther. 2011;35(4):351\u201364.","journal-title":"J Vet Pharmacol Ther"},{"key":"4760_CR20","unstructured":"European Medicines Agency, Committee for Medicinal Products for Veterinary Use, Trifexis European Product Information. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trifexis-epar-product-information_en.pdf. Accessed 25 Nov 2020."},{"issue":"538","key":"4760_CR21","first-page":"1","volume":"10","author":"EA Kuntz","year":"2017","unstructured":"Kuntz EA, Kammanadiminti S. Safety evaluation of lotilaner in dogs after oral administration as flavoured chewable tablets (Credelio). Parasit Vectors. 2017;10(538):1\u20136.","journal-title":"Parasit Vectors."},{"key":"4760_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jvp.12375","volume":"40","author":"M Drag","year":"2017","unstructured":"Drag M, Saik J, Harriman J, Letendre L, Yoon S, Larsen D. Safety evaluation of orally administered afoxolaner and milbemycin oxime in eight-week-old dogs. J Vet Pharmacol Therap. 2017;40:447\u201353.","journal-title":"J Vet Pharmacol Therap."},{"key":"4760_CR23","first-page":"493","volume":"183","author":"R Seward","year":"1983","unstructured":"Seward R. Reactions to dogs given ivermectin. (Letters to the Editors). J Am Vet Med. 1983;183:493.","journal-title":"J Am Vet Med"},{"key":"4760_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00008571-200111000-00012","volume":"11","author":"K Mealey","year":"2001","unstructured":"Mealey K, Bentjen S, Gay J, Cantor J. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001;11:727\u201333.","journal-title":"Pharmacogenetics"},{"issue":"2","key":"4760_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cvsm.2011.12.005","volume":"42","author":"VM Merola","year":"2012","unstructured":"Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(2):313\u201333. https:\/\/doi.org\/10.1016\/j.cvsm.2011.12.005.","journal-title":"Vet Clin North Am Small Anim Pract."},{"issue":"7","key":"4760_CR26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2460\/ajvr.1991.52.07.1170","volume":"52","author":"WJ Tranquilli","year":"1991","unstructured":"Tranquilli WJ, Paul AJ, Todd KS. Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies. Am J Vet Res. 1991;52(7):1170\u20132.","journal-title":"Am J Vet Res"},{"issue":"1","key":"4760_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2460\/ajvr.71.1.115","volume":"71","author":"JG Sherman","year":"2010","unstructured":"Sherman JG, Paul AJ, Firkins LD. Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation. Am J Vet Res. 2010;71(1):115\u20139.","journal-title":"Am J Vet Res"},{"key":"4760_CR28","unstructured":"ESCCAP. Worm control in dogs and cats. Guideline 01, Sixth Edition; February 2020. http:\/\/www.esccap.org. Accessed 25 Nov 2020."},{"key":"4760_CR29","unstructured":"Companion Animal Parasite Council. CAPC guidelines; 2017 and 2020. https:\/\/capcvet.org\/guidelines\/. Accessed 30 Mar 2021."},{"key":"4760_CR30","doi-asserted-by":"publisher","first-page":"109167","DOI":"10.1016\/j.vetpar.2020.109167","volume":"283","author":"F Dantas-Torres","year":"2020","unstructured":"Dantas-Torres F, et al. TroCCAP recommendations for the diagnosis, prevention and treatment of parasitic infections in dogs and cats in the tropics. Vet Parasitol. 2020;283:109167.","journal-title":"Vet Parasitol."},{"key":"4760_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.vetpar.2006.11.013","volume":"145","author":"E Grandemange","year":"2007","unstructured":"Grandemange E, Claerebout E, Genchi C, Franc M. Field evaluation of the efficacy and the safety of a combination of oxantel\/pyrantel\/praziquantel in the treatment of naturally acquired gastrointestinal nematode and\/or cestode infestations in dogs in Europe. Vet Parasitol. 2007;145:94.","journal-title":"Vet Parasitol"},{"key":"4760_CR32","unstructured":"European Scientific Counsel Companion Animal Parasites. ESCCAP:\u00a0Endoparasites. https:\/\/www.esccap.org\/parasites\/Endoparasites\/1\/. Accessed 25 Nov 2020."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-021-04760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-021-04760-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-021-04760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T18:07:39Z","timestamp":1725127659000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-021-04760-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4760"],"URL":"https:\/\/doi.org\/10.1186\/s13071-021-04760-z","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was based on the guidelines for evaluating the target animal safety of new pharmaceuticals [VICH Guideline 43, and to recognized quality assurance standards (United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations, 21 Code of Federal Regulations (CFR) Part 58 and the Organisation for Economic Co-operation and Development (OECD) Series on Principles of Good Laboratory Practice)]. The study was reviewed and approved by the CRL-Ashland\u2019s Institutional Animal Care and Use Committee. This manuscript was prepared in compliance with the ARRIVE Guidelines Checklist for animal in vivo experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"These studies were funded by Elanco Animal Health. All authors are employees of Elanco Animal Health. The handling editors have been involved in consulting services (Filipe Dantas-Torres), research projects (Pablo Jes\u00fasBorr\u00e1s, Filipe Dantas-Torres, Adnan Hod\u017eic) and meetings (Filipe Dantas-Torres) sponsored by different veterinary pharmaceutical companies in the past 10 years, including Elanco. They declare that each manuscript in this collectionwas handled impartially and peer reviewed rigorously by at least two independent external reviewers.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}